Lipoprotein and Apolipoproteins With Metabolic Liver Diseases
NCT ID: NCT03220971
Last Updated: 2018-04-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
440 participants
OBSERVATIONAL
2017-09-20
2019-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Multicenter Prospective Study of Application of Platelet Mapping in Acute-on-chronic-liver Failure in China
NCT04119973
Frequency of Metabolic Dysfunction Associated Fatty Liver Disease in Patients With Acute Coronary Syndromes
NCT06456970
Proteomic Analysis of Human Hepatocellular Carcinoma
NCT01177631
Follow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease
NCT02863757
Metabolic Syndrome and Fatty Liver Disease Among Egyptian Patients with Chronic HBV
NCT06589167
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
proposed cross-section study
1. 100 subjects with NAFLD/NASH and negative anti-HCV Ab
2. 50 subjects with HCC and negative anti-HCV Ab
3. 50 subjects with HCC and positive for genotype-1 HCV
4. 50 controls with all negative for NAFLD/NASH but positive for genotype-1 HCV
5. 50 controls with all negative for NAFL, NASH and HCV
lipoprotein and apolipoproteins
To find out the role of lipoprotein and apolipoproteins (apos) in pathogenic hepatic diseases
proposed longitudinal study
1. 50 NAFLD/NASH patients and positive for genotype-1 HCV with SVR
2. 10 NAFLD/NASH patients and positive for genotype-1 HCV without SVR
3. 10 HCC patients and positive for genotype-1 HCV with SVR
4. 10 HCC patients and positive for genotype-1 HCV without SVR
5. 50 chronic hepatitis C but not NAFLD patients with SVR
6. 10 chronic hepatitis C but not NAFLD patients without SVR
lipoprotein and apolipoproteins
To find out the role of lipoprotein and apolipoproteins (apos) in pathogenic hepatic diseases
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
lipoprotein and apolipoproteins
To find out the role of lipoprotein and apolipoproteins (apos) in pathogenic hepatic diseases
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. nonalcoholic fatty liver disease
3. Non-Alcoholic Steatohepatitis
Exclusion Criteria
\-
20 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chun-Hsiang Wang
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chun-Hsiang Wang
Tainan Municipal Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chun-Hsiang Wang
Tainan City, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1060603
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.